ClinicalTrials.gg
TerminatedNCT00067041Updated Mar 7, 2013

Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

A Phase 2/3 interventional study of Remodulin (treprostinil sodium) Injection in Peripheral Vascular Disease, sponsored by United Therapeutics. Terminated at 4 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2013-03-07.

Primary conditionChronic Limb-Threatening IschemiaRegistry: Peripheral Vascular DiseasesReclassifiedWhy we changed it
Registry
Peripheral Vascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Limb-Threatening Ischemia
Why
  1. The study's title name Chronic Limb-Threatening Ischemia, a narrower term within Peripheral Vascular Diseases.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by United Therapeutics · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States — 13 open to participants now, 20 under way, 2 of them phase 3. Chronic Limb-Threatening Ischemia · United States.

Enrollment
47th of 82
30 · median 38
Started
2003
with 2 others
Phase 2/3
Only one
of the 105
Registered
3rd of 105
by date

Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, this one is the 47th largest by enrollment of the 82 interventional ones that give a count, is one of 3 that started in 2003, is the only one in phase 2/3, and was the 3rd registered.

Chronic Limb-Threatening Ischemia

358 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

13 of the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, or all of them as a file.
02

Study summary

Approximately 30 patients will be enrolled in this 12-week study designed to assess the effect of continuous subcutaneous Remodulin therapy on the outcome of infrainguinal bypass grafts in patients with critical limb ischemia (CLI). Portions of the study will be conducted in the hospital and on an out-patient basis. The study will be conducted at multiple centers.

03

Conditions studied

  • Peripheral Vascular Disease

Browse trials for

Keywords

  • Critical Limb Ischemia
  • Autogenous Bypass Graft
  • CLI
04

In context

Chronic Limb-Threatening Ischemia Reclassified

358 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

This study's enrollment of 30 is below the median of 41 across 240 interventional studies indexed under Chronic Limb-Threatening Ischemia.

Browse Chronic Limb-Threatening Ischemia studies →

Lead sponsor

United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Vascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Patients with critical limb ischemia and an appropriate reference lower-limb ischemic wound due to documented peripheral arterial disease who have had an autogenous vein infrainguinal bypass graft performed immediately prior to study initiation.
06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
30 participants
07

Study locations

4 sites
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • University of Massachusetts Memorial Health Center
    Worcester, Massachusetts 01655, United States
  • Vascular Institute Albany Medical College
    Albany, New York 12208, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003, a primary completion of Dec 2003 and a completion of Dec 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2003
First posted
Aug 13, 2003
Start
Mar 2003
Primary completionActual
Dec 2003
CompletionActual
Dec 2003
Last update
Mar 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00067041
Responsible party
Sponsor
First posted
Aug 13, 2003
Start date
Mar 2003
Primary completion
Dec 2003
Completion
Dec 2003
Last update
Mar 7, 2013
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion